Fluicell AB
Research Fluicell AB (FLUI) on Bullrun: market cap SEK 40.25M, P/E 14.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFLUI
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 40.25M
- P/E14.4
- Financial periodQ1 2026
- RevenueSEK 6.09M
- Net incomeSEK 3.31M
- Free cash flow-SEK 984.00K
- Gross margin116.8%
Valuation Snapshot
latest market cap is SEK 40.25M; P/E is 14.4.
Peer valuation comparison
Latest P/E is 14.43x versus a Healthcare sector median of 24.61x (41.3% below).
Latest P/E is 14.43x versus a Sweden median of 18.18x (20.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 6.00M | -SEK 8.33M | -SEK 13.66M | 218.8% | -6.07 | SEK 2.26M | n/a | SEK 10.90M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-30 | SEK 40.25M | 14.4 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Fluicell AB
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Fluicell AB's market cap?
Fluicell AB's market capitalization is SEK 40.25M.
What is Fluicell AB's P/E ratio?
Fluicell AB's price-to-earnings (P/E) ratio is 14.4.
What does Fluicell AB do?
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration.